Clinical trials
Patient clinical trials
Below are recruiting patient clinical trials, each written for real people, not researchers. We’re tracking 14,207 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06862063Recruiting
Genetic study of spontaneous neck artery tears
This study looks at the genes of people who have had a spontaneous tear in a neck artery. It aims to find if there is an underlying genetic cause, which could help guide treatment for you and your family.
Rome, LazioAges 18 years+ - NCT06862297Recruiting
Comparing a new jaw tracking device to standard sleep study for sleep apnea
This study compares a new device that tracks jaw movement during sleep to the standard sleep study (polysomnography) for diagnosing sleep apnea. You may be eligible if you have symptoms like loud snoring or daytime sleepiness and have been referred for a sleep study.
TaipeiAges 20–75 - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT06482502Recruiting
Testing arm function in Parkinson's with a ring and board test
This study checks if a 6-minute pegboard and ring test is a valid way to measure arm function in people with Parkinson's. It may help find better ways to track arm movement issues.
IstanbulAges 45–75 - NCT06601127RecruitingPhase 2
Tiprogrel for recent minor stroke or high-risk TIA
This trial tests a new anti-platelet drug called Tiprogrel to prevent another stroke in people who recently had a minor stroke or a transient ischemic attack (TIA) with certain artery narrowing or plaques. It aims to see if this medicine is safe and works better than current treatments.
Shenyang, LiaoningAges 40 years+ - NCT06605586RecruitingPhase 1/Phase 2
Test of tasquinimod for myelofibrosis that stopped responding to JAK inhibitor therapy
This trial tests an oral drug called tasquinimod for people with myelofibrosis that no longer responds to or cannot take a JAK inhibitor. The goal is to see if tasquinimod can help shrink an enlarged spleen and improve symptoms.
AachenAges 18 years+ - NCT06660719RecruitingPhase 3
New stroke medicine SP-8203 with clot-busting therapy
This trial tests a new medicine called SP-8203 added to standard clot-busting treatment for people having a moderate to severe stroke. The goal is to see if it helps improve recovery and is safe.
BusanAges 19–85 - NCT06852976RecruitingPhase 2
Gel treatment for diabetic foot ulcers study
This trial tests a new gel (MDI-1228-mesylate) applied to diabetic foot ulcers to see if it helps them heal faster than standard care alone. It is for people who have had a foot ulcer for at least 12 weeks and are already receiving standard treatment.
Durham, North CarolinaAges 18–75 - NCT06863844Recruiting
DNA markers for predicting outcomes in urothelial cancer
This trial studies DNA markers in tumor tissue or blood samples to see if they can predict how well treatments work or how the cancer behaves. It may help doctors better understand and manage urothelial cancer in the future.
BolognaAges 18 years+ - NCT07328425RecruitingPhase 2
A study of lurbinectedin and irinotecan for advanced DSRCT
This trial tests a combination of two chemotherapy drugs (lurbinectedin and irinotecan) for people with desmoplastic small round cell tumor (DSRCT) that has spread or cannot be removed by surgery. It is for patients whose cancer has gotten worse after at least one prior treatment.
Candiolo, TorinoAges 15 years+ - NCT06865274Recruiting
A look at gene changes in MS, NMOSD, and MOGAD
This study looks at a specific gene change in people with MS, NMOSD, or MOGAD to see how common it is. By joining, you help researchers learn more about these conditions and possible future treatments.
Roma, RomaAges 18 years+ - NCT06863532Recruiting
Comparing two add-on treatments for type 2 diabetes
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
Hangzhou, ZhejiangAges 18–74 - NCT07326488RecruitingPhase 1/Phase 2
Study of MHB009C for advanced solid tumors
This trial tests a new drug called MHB009C for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07326540RecruitingPhase 3
Testing a new antibiotic for drug-resistant pneumonia in the hospital
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
TbilisiAges 18–82 - NCT07324837RecruitingPhase 3
Study of a clot-busting drug for stroke up to 24 hours later
This trial tests a single dose of a new clot-dissolving medicine for people who had a stroke 4.5 to 24 hours ago. It may help if you cannot have standard treatments like a clot-removal procedure or other clot-busting drugs.
Ryazan, Ryazan OblastAges 18 years+ - NCT07331155RecruitingPhase 2
LBL-024 combo for advanced esophageal cancer
This trial tests a new drug combination for advanced solid tumors, specifically esophageal cancer. It may help people whose cancer has not responded to other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07329322RecruitingPhase 2
Drug combo before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
BeijingAges 18–75 - NCT07330245Recruiting
Study of anifrolumab for lupus patients needing treatment
This study looks at how well anifrolumab works for people with systemic lupus erythematosus (SLE) who are starting it for the first time. It aims to see if patients can achieve a low disease activity state (LLDAS5) after treatment.
Monserrato, CAAges Any age - NCT07330258Recruiting
Observing Parkinson's over time in people still having movement symptoms
This study follows people with Parkinson's disease who still have movement symptoms despite taking medication. It aims to understand how the disease changes over time, which could help improve future treatments.
Phoenix, ArizonaAges 45–75 - NCT07331285Recruiting
Genio therapy study for moderate to severe sleep apnea
This trial studies a device called Genio that is implanted to help keep your airway open while you sleep. It is for people with moderate to severe sleep apnea who have not been helped by other treatments.
Miami, FloridaAges 22 years+ - NCT07332000RecruitingPhase 2
Gene therapy and radiation for intermediate-risk prostate cancer
This trial tests a new gene therapy (aglatimagene besadenovec) given as an injection into the prostate before standard radiation therapy for men with intermediate-risk prostate cancer. The goal is to see if adding this treatment can improve outcomes.
Peoria, ArizonaAges 18 years+ - NCT06865235Recruiting
Glaucoma and cataract surgery with a new device
This trial tests a surgery that combines cataract removal with a new technique to lower eye pressure in people who have both primary open-angle glaucoma and cataracts. It aims to see if this combined surgery is safe and effective.
Belo Horizonte, Minas GeraisAges 40 years+ - NCT06863857Recruiting
CT Scan to Check Response to First Kidney Cancer Treatment
This study uses a special CT scan to see how well your first treatment for kidney cancer that has spread is working. It looks at people with clear cell renal cell carcinoma who are starting immunotherapy combined with a targeted drug or two immunotherapy drugs.
Bologna, BOAges 18 years+ - NCT07327242Enrolling by invitation
AI tool to improve eye test accuracy in glaucoma patients
This trial tests if a large language model tool can help patients perform more reliable visual field tests. It may improve detection of glaucoma progression.
Palo Alto, CaliforniaAges 18 years+
Hear when a new Patient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient?
- Yes. Clin2 currently lists 14,207 recruiting patient studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.